Cancer Imaging Research Program

癌症成像（CI）研究 项目总结/摘要 癌症成像（CI）计划是一个跨学科的计划，整合成像工程研究 癌症生物学的研究。该计划的目标是建立新的成像技术， 识别癌症生物学机制，设计新的靶向治疗，开发创新的 用于改善患者护理的成像模式。CI计划涵盖了连续的成像研究 从“分子到小鼠再到人”，这构成了以下三个具体目标的基础：（1）利用 研究癌症发病机制和开发癌症靶向治疗的成像剂，（2）编码 可量化的成像指标，以研究癌症生物学和改善癌症治疗，和（3）翻译新的 成像方法学应用于患者护理。这些目标反映了主要工作组和主动行动， 吸引来自基础生物学，医学，化学，物理学和工程背景的研究人员与其他 癌症中心的研究人员通过跨项目合作取得了极具影响力的进展 在成像和纳米医学领域。广泛使用一系列共享资源，特别是成像、无胸腺、 细胞计数和生物统计学促进成员发现的各个方面。 在James Basilion（联合负责人）和Zhenghong Lee（联合负责人）的领导下，CI计划有29个 成员包括19名正式成员、2名副成员和8名临床成员。成员来自9个部门， 总计810万美元的研究资助资金（年度直接成本），其中730万美元用于同行评审，400万美元用于研究。 是国家癌症研究所资助的在2012年至2016年期间，CI计划成员发表了639篇出版物。癌症和 与计划相关的出版物包括27%的计划间出版物，25%的计划内出版物，10%的计划间和计划内出版物。 7%涉及与另一个癌症中心的合作。这个高效的项目 在成像和纳米医学方面取得了重大进展。例子包括：发现和国际 基于随机磁波产生（MR）的新型定量MRI成像分析工具的分布 指纹识别）;开发新型纳米颗粒诊断和治疗剂，包括植物来源的病毒 颗粒，以刺激肿瘤的宿主免疫排斥，目前在患有黑素瘤的狗的临床研究中; 用于检测乳腺癌微转移的纤连蛋白靶向剂的产生;以及 一种用于在微观尺度上跟踪纳米颗粒的布置的多模式体内成像方法， 以及在活体动物中观察肿瘤的微血管。

CANCER IMAGING (CI) RESEARCH PROGRAM PROJECT SUMMARY/ABSTRACT The Cancer Imaging (CI) Program is a transdisciplinary program that integrates imaging engineering research with the study of cancer biology. The goals of this program are to build novel imaging technologies for discerning mechanisms of cancer biology, designing new targeted therapies, and developing innovative imaging modalities for improving patient care. The CI program covers a continuum of imaging research reaching from “molecules to mice to man” that forms the basis for the following three Specific Aims: (1) Utilize imaging agents to study cancer pathogenesis and develop cancer-targeting therapeutics, (2) Codify quantifiable imaging metrics to study cancer biology and improve cancer treatments, and (3) Translate novel imaging methodologies to patient care. These aims reflect major working groups and initiatives that actively engage researchers from basic biology, medicine, chemistry, physics, and engineering backgrounds with other Cancer Center investigators through inter-programmatic collaborations that result in highly impactful advances in imaging and nanomedicine. Extensive use of an array of shared resources, in particular Imaging, Athymic, Cytometry, and Biostatistics facilitate all aspects of member discoveries. Under the leadership of James Basilion (Co-Leader) and Zhenghong Lee (Co-Leader) the CI Program has 29 members including 19 full, 2 associate, and 8 clinical members. Members represent 9 departments, giving rise to a total of $8.1M in research grant funding (annual direct costs), of which $7.3M is peer-reviewed and $4.0M is NCI-funded. Between 2012 and 2016, CI program members published 639 publications. Cancer and program related publications included 27% inter-programmatic, 25% intra-programmatic, 10% inter- and intra- programmatic and 7% that involved collaborations with another Cancer Center. This highly effective program has made major advances in imaging and nanomedicine. Examples include: the discovery and international distribution of a novel quantitative MRI imaging analysis tool based on random magnetic wave generation (MR fingerprinting); development of novel nanoparticle diagnostics and therapeutics, including plant derived viral particles to stimulate host immune rejection of tumors that is now in clinical studies in dogs with melanoma; generation of a fibronectin-targeting agent for detection of breast cancer micrometastases; and the invention of a multimodal in vivo imaging method for following the disposition of nanoparticles on a microscopic scale as well as visualizing the microvasculature of tumors in live animals.